# A Study For Treatment of Paroxysmal Atrial Fibrillation (PAF) With the OMNYPULSE Catheter and the TRUPULSE Generator

Study · id `cardio:ct-nct05971693` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05971693](<https://clinicaltrials.gov/study/NCT05971693>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05971693

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 188 participants.

## Technical summary

Registry record NCT05971693. Allocation not applicable; no masking; primary purpose treatment. Start 2023-09-12 (actual); primary completion 2024-12-10 (actual). Results posted on 2026-03-25.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 188 participants (enrolled count; ClinicalTrials.gov record NCT05971693, source copy `cardio:ctgov-nct05971693-2026-09-29`, retrieved 2026-11-18)
- Started: 2023-09-12 (actual) (ClinicalTrials.gov record NCT05971693, source copy `cardio:ctgov-nct05971693-2026-09-29`, retrieved 2026-11-18)
- Primary completion: 2024-12-10 (actual) (ClinicalTrials.gov record NCT05971693, source copy `cardio:ctgov-nct05971693-2026-09-29`, retrieved 2026-11-18)
- Completion: 2025-09-05 (actual) (ClinicalTrials.gov record NCT05971693, source copy `cardio:ctgov-nct05971693-2026-09-29`, retrieved 2026-11-18)
- Results first posted: 2026-03-25 (ClinicalTrials.gov record NCT05971693, source copy `cardio:ctgov-nct05971693-2026-09-29`, retrieved 2026-11-18)
- Countries: Belgium; Canada; Croatia; Czechia; Germany; Italy; Lithuania; Netherlands (ClinicalTrials.gov record NCT05971693, source copy `cardio:ctgov-nct05971693-2026-09-29`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05971693-2026-09-29`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study For Treatment of Paroxysmal Atrial Fibrillation (PAF) With the OMNYPULSE Catheter and the TRUPULSE Generator
- Acronym: Omny-IRE
- Condition: Atrial Fibrillation
- Intervention (Device): OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator
- Lead sponsor: Biosense Webster, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Biosense Webster, Inc. (`cardio:org-biosense-webster-inc`)

## Provenance

Content hash: e6280cafb3936fe8dbf9aa01eb45375a576661f47d602550dd16a0a6f5063e6b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
